This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, J. Articles by Henkin, J. Search for Related Content PubMed PubMed Citation Articles by Wang, J. Articles by Henkin, J.

Tumor Suppression by a Rationally Designed Reversible Inhibitor of Methionine Aminopeptidase-2

Cancer Research,
Advanced Technology,
Preclinical Safety, Global Pharmaceutical R & D, Abbott Laboratories, Abbott Park, Illinois,
Departments of Surgery and
Pediatric Oncology, The University of Pennsylvania School of Medicine and The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Methionine aminopeptidase (MetAP)-2 has been suggested as a novel target for cancer therapy because the anticancer agent TNP-470 irreversibly inactivates the catalytic activity of this enzyme. However, the importance of MetAP2 in cell growth and tumor progression was uncertain because previous data were based on the chemically reactive TNP-470. Here we show that a rationally designed reversible MetAP2 inhibitor, A-357300, suppresses tumor growth preclinically without the toxicities observed with TNP-470. We have synthesized this bestatin-type MetAP2 inhibitor with the aid of crystal structures of the enzyme-inhibitor complexes and parallel synthesis. A-357300 induces cytostasis by cell cycle arrest at the G₁ phase selectively in endothelial cells and in a subset of tumor cells, but not in most primary cells of nonendothelial type. A-357300 inhibits angiogenesis both in vitro and in vivo and shows potent antitumor efficacy in carcinoma, sarcoma, and neuroblastoma murine models. These data affirm that MetAP2 plays a pivotal role in cell growth and establish that reversible MetAP2 inhibitors are promising novel cancer therapeutic agents.

This article has been cited by other articles:

				J. Wang, L. A. Tucker, J. Stavropoulos, Q. Zhang, Y.-C. Wang, G. Bukofzer, A. Niquette, J. A. Meulbroek, D. M. Barnes, J. Shen, et al. Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor PNAS, February 12, 2008; 105(6): 1838 - 1843. [Abstract] [Full Text] [PDF]

				D. Kass, R. S. Bridges, A. Borczuk, and S. Greenberg Methionine Aminopeptidase-2 as a Selective Target of Myofibroblasts in Pulmonary Fibrosis Am. J. Respir. Cell Mol. Biol., August 1, 2007; 37(2): 193 - 201. [Abstract] [Full Text] [PDF]

				X. Chen, C. R. Chong, L. Shi, T. Yoshimoto, D. J. Sullivan Jr., and J. O. Liu From the Cover: Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity PNAS, September 26, 2006; 103(39): 14548 - 14553. [Abstract] [Full Text] [PDF]

				J.-R. J. Yeh, R. Ju, C. M. Brdlik, W. Zhang, Y. Zhang, M. E. Matyskiela, J. D. Shotwell, and C. M. Crews Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest PNAS, July 5, 2006; 103(27): 10379 - 10384. [Abstract] [Full Text] [PDF]

				M. J. Morowitz, R. Barr, Q. Wang, R. King, N. Rhodin, B. Pawel, H. Zhao, S. A. Erickson, G. S. Sheppard, J. Wang, et al. Methionine Aminopeptidase 2 Inhibition Is an Effective Treatment Strategy for Neuroblastoma in Preclinical Models Clin. Cancer Res., April 1, 2005; 11(7): 2680 - 2685. [Abstract] [Full Text] [PDF]

				H. Nakagawa, S. Koyanagi, T. Takiguchi, Y. Kuramoto, S. Soeda, H. Shimeno, S. Higuchi, and S. Ohdo 24-Hour Oscillation of Mouse Methionine Aminopeptidase2, a Regulator of Tumor Progression, Is Regulated by Clock Gene Proteins Cancer Res., November 15, 2004; 64(22): 8328 - 8333. [Abstract] [Full Text] [PDF]